In the field of medicine and health products, empty capsules, as an important carrier of drugs and nutrients, are on a fast track of development, and their technological innovation and market expansion present remarkable highlights.
From the perspective of capacity expansion, labor enterprises are actively deploying and striving to seize the initiative in the fierce market competition. Ningbo Jiangnan Capsule Co., Ltd. has a capsule production background of more than 20 years. Founded in 1992, as a Sino-foreign joint venture focusing on the research and development, production and sales of medicinal hollow capsules, it has always been at the forefront of the industry. The company has formulated an ambitious capacity expansion plan, planning to build 32 empty capsule production lines in four phases. After all the construction, the annual production capacity will reach 24 billion empty capsules, which will undoubtedly greatly enhance its supply capacity and competitive advantage in the market.
In the workshop, the fully enclosed central air-conditioning system accurately controls the temperature and humidity, always maintaining the most suitable production environment. At the same time, high-precision detection methods are introduced, and strict quality control is carried out from the sharing of raw materials to the completion of each process, without missing any control link. Jiangnan Company not only performs well in basic production, but also highlights service awareness this time. It can provide capsule monochrome, overall, circumferential, and directional printing services according to the customer's aseptic needs, and the personality of different customers. In addition, the company always adheres to technological innovation, continuously invests resources in research and development, and further improves the management system. From personnel training, process optimization to quality monitoring, every link is refined to ensure that the quality of mass production has a high degree of stability and continuity, and provide the market with a steady stream of high-quality hollow targets. The growth of market demand has also injected strong development momentum into the industry. With the improvement of people's health awareness, the demand for medicines and health products continues to rise. Taking the treatment of rare diseases as an example, the new version of the National Medical Insurance Drug Catalog was implemented on November 1, adding 13 new rare diseases, among which No vartis's Ferheda ® (Ipcopan Hydrochloride Capsules) is used to treat paroxysmal nocturnal erythruria (PNH).
Previously, this disease was mostly treated with injections or supplements, which caused inconvenience. The capsule dosage form greatly improved the convenience and treatment compliance of patients, highlighting the huge potential of capsule preparations in future drug development, especially in the field of rare disease treatment. This also prompted pharmaceutical companies to put forward requirements for the quality and performance innovation design of empty capsules.